- Home
- GHLD vs XNCR Comparison
GHLD vs XNCR Comparison
Compare GHLD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHLD
- XNCR
- Stock Information
- Founded
- GHLD 1960
- XNCR 1997
- Country
- GHLD United States
- XNCR United States
- Employees
- GHLD N/A
- XNCR N/A
- Industry
- GHLD Finance: Consumer Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- GHLD Finance
- XNCR Health Care
- Exchange
- GHLD Nasdaq
- XNCR Nasdaq
- Market Cap
- GHLD 1.2B
- XNCR 1.1B
- IPO Year
- GHLD 2020
- XNCR 2013
- Fundamental
- Price
- GHLD $19.88
- XNCR $14.71
- Analyst Decision
- GHLD Hold
- XNCR Buy
- Analyst Count
- GHLD 6
- XNCR 11
- Target Price
- GHLD $18.10
- XNCR $24.20
- AVG Volume (30 Days)
- GHLD 29.0K
- XNCR 1.5M
- Earning Date
- GHLD 11-05-2025
- XNCR 11-06-2025
- Dividend Yield
- GHLD 3.77%
- XNCR N/A
- EPS Growth
- GHLD N/A
- XNCR N/A
- EPS
- GHLD 0.42
- XNCR N/A
- Revenue
- GHLD $1,125,872,000.00
- XNCR $146,929,000.00
- Revenue This Year
- GHLD $1.42
- XNCR $22.09
- Revenue Next Year
- GHLD $22.36
- XNCR N/A
- P/E Ratio
- GHLD $47.60
- XNCR N/A
- Revenue Growth
- GHLD 23.19
- XNCR N/A
- 52 Week Low
- GHLD $11.21
- XNCR $6.92
- 52 Week High
- GHLD $23.57
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- GHLD 48.38
- XNCR 61.57
- Support Level
- GHLD $19.83
- XNCR $12.17
- Resistance Level
- GHLD $19.93
- XNCR $15.50
- Average True Range (ATR)
- GHLD 0.07
- XNCR 1.25
- MACD
- GHLD -0.01
- XNCR -0.08
- Stochastic Oscillator
- GHLD 47.83
- XNCR 78.41
About GHLD Guild Holdings Company
Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.